Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old

DOI: 10.1128/AAC.01657-18

Article Information

DOI

PubMed

Published By

History

^aCollege of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA
^bDepartment of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
^cDirectorate of Child Health, Komfo Anokye Teaching Hospital, Kumasi, Ghana
^dDepartment of Child Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
^eDeaprtment of Medicine, The Miriam Hospital, Providence, Rhode Island, USA
^fDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
^gDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA
^hDepartment of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
ⁱProgram in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA
^jGraduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences and Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts, USA

Address correspondence to Awewura Kwara, awewura.kwara{at}medicine.ufl.edu.
Citation Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ. 2019. Effect of rifampin-isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children 3 to 14 years old. Antimicrob Agents Chemother 63:e01657-18. https://doi.org/10.1128/AAC.01657-18.